Lymphatic endothelial cells efferent to inflamed joints produce iNOS and inhibit lymphatic vessel contraction and drainage in TNF-induced arthritis in mice.

Abstract

BACKGROUND:

In this study, we sought to determine the cellular source of inducible nitric oxide synthase (iNOS) induced in lymphatic endothelial cells (LECs) in response to tumor necrosis factor (TNF), the effects of iNOS on lymphatic smooth muscle cell (LSMC) function and on the development of arthritis in TNF-transgenic (TNF-Tg) mice, and whether iNOS inhibitors improve lymphatic function and reduce joint destruction in inflammatory erosive arthritis.

METHODS:

We used quantitative polymerase chain reactions, immunohistochemistry, histology, and near-infrared imaging to examine (1) iNOS expression in podoplanin + LECs and lymphatic vessels from wild-type (WT) and TNF-Tg mice, (2) iNOS induction by TNF in WT LECs, (3) the effects of iNOS inhibitors on expression of functional muscle genes in LSMCs, and (4) the effects of iNOS inhibitors on lymphatic vessel contraction and drainage, as well as the severity of arthritis, in TNF-Tg mice.

RESULTS:

LECs from TNF-Tg mice had eight fold higher iNOS messenger RNA levels than WT cells, and iNOS expression was confirmed immunohistochemically in podoplanin + LECs in lymphatic vessels from inflamed joints. TNF (0.1 ng/ml) increased iNOS levels 40-fold in LECs. LSMCs cocultured with LECs pretreated with TNF had reduced expression of functional muscle genes. This reduction was prevented by ferulic acid, which blocked nitric oxide production. Local injection of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide into inflamed paws of TNF-Tg mice resulted in recovery of lymphatic vessel contractions and drainage. Treatment of TNF-Tg mice with ferulic acid reduced synovial inflammation as well as cartilage and bone erosion, and it also restored lymphatic contraction and drainage.

CONCLUSIONS:

iNOS is produced primarily by LECs in lymphatic vessel efferent from inflamed joints of TNF-Tg mice in response to TNF and inhibits LSMC contraction and lymph drainage. Ferulic acid represents a potential new therapy to restore lymphatic function and thus improve inflammatory arthritis by inhibiting local production of nitric oxide by LSMCs.

• Authors: Qianqian Liang, Yawen Ju, Yan Chen, Wensheng Wang, Jinlong Li, Li Zhang, Hao Xu, Ronald W Wood, Edward M Schwarz, Brendan F Boyce, Yongjun Wang, Lianping Xing
• Journal: Arthritis research & therapy (Arthritis Res Ther) Vol. 18 Pg. 62 (Mar 12 2016) ISSN: 1478-6362 [Electronic] England
• PMID: 26970913 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Coumaric Acids
• Free Radical Scavengers
• Tumor Necrosis Factor-alpha
• ferulic acid
• Nitric Oxide Synthase Type II
• Nos2 protein, mouse

Topics

• Animals
• Arthritis, Experimental (metabolism, pathology)
• Arthritis, Rheumatoid (metabolism, pathology)
• Blotting, Western
• Coumaric Acids (pharmacology)
• Endothelial Cells (metabolism)
• Flow Cytometry
• Free Radical Scavengers (pharmacology)
• Immunohistochemistry
• Inflammation (metabolism, pathology)
• Lymphatic Vessels (metabolism)
• Mice
• Mice, Inbred C57BL
• Mice, Transgenic
• Muscle Contraction (physiology)
• Muscle, Smooth (metabolism)
• Nitric Oxide Synthase Type II (biosynthesis)
• Real-Time Polymerase Chain Reaction
• Tumor Necrosis Factor-alpha